IRAK DEGRADERS AND USES THEREOF
Search Report
EP4613773A3
Kind: A3
Mar 18, 2026
Applicants
Kymera Therapeutics, Inc.
Inventors
MAINOLFI, Nello, JI, Nan, KLUGE, Arthur F., WEISS, Matthew M., ZHANG, Yi
Abstract
The present invention relates to compounds and methods useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation by compounds according to the present invention. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
IPC Classifications
C07D 401/14 20060101AFI20260210BHEP
C07D 413/14 20060101ALI20260210BHEP
C07D 417/14 20060101ALI20260210BHEP
C07D 471/04 20060101ALI20260210BHEP
C07D 487/04 20060101ALI20260210BHEP
C07D 493/04 20060101ALI20260210BHEP
A61K 39/395 20060101ALI20260210BHEP
A61K 47/64 20170101ALI20260210BHEP
A61K 47/68 20170101ALI20260210BHEP
C07K 16/00 20060101ALI20260210BHEP
C07K 16/18 20060101ALI20260210BHEP
C07K 16/28 20060101ALI20260210BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR